|
|
 |
|
Viewing report
|
|
|
|
Premium Company Profile Celgene
Datamonitor, Oct 2007, Pages: 58
Introduction
Celgene is engaged in the discovery, development, and commercialization of therapies for the treatment of cancer and immunological diseases. Among seven marketed products, the companys lead product is Revlimid, an analog of thalidomide that is approved by the FDA for the treatment of MDS patients with the 5q chromosomal deletion and for the treatment of relapsed/refractory myeloma.
Scope
- Contains corporate strategy, value chain presence and SWOT Analysis
- Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
- Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
The companys major contributor to revenue growth during 2002-2006 was product sales which increased at an absolute growth of +$689 million during the period During fiscal 2006, the company generated approximately 90.3% of total revenues from product sales. Sales of Thalomid were $433 million during the year whereas Revlimid provided $321 million contributing collectively 84% of the total revenues in 2006 Celgenes biggest contributor to sales growth out to 2010 will be revenues from Revlimid sales. This is mainly due to the expectation that Revlimid will eventually become the most preferred therapy for multiple myeloma
Reasons to Purchase
- Access all the important information and analysis on the company in a single report
- Understand companys strengths, weaknesses, opportunities and threats along with business strategy and value chain
- Gain access to companys adjusted five year financial data along with key ratios and market capitalization
Customers who bought this item also bought
Celgene Corporation: PharmaVitae Profile
Celgene Corporation - SWOT Analysis
Celgene Corporation - Financial and Strategic Analysis Review
Celgene Corporation
Celgene Corporation: PharmaVitae Model
Analysis of Celgene Corporation
Acquisition of Pharmion Corporation by Celgene Corporation Call - Celgene Corp. - Earnings Transcript
Multiple Myeloma Therapeutics - US Market Trends & Analysis
Celgene Corporation-Detailed Product Pipeline
Multiple Myeloma Therapeutics - Global Strategic Business Report
Stakeholder Opinions: Multiple Myeloma - Exploring new targets for multiple drug therapy
Canaccord Adams Global Growth Conference - Celgene Corp., - Earnings Transcript
|
|
|
|
